Explore how strategic intelligence agencies and competitive intelligence solutions are shaping the pharmaceutical industry. Download our guide to technological advancements and more invaluable ...

The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to meet its primary and secondary endpoint.

MSD has received the UK MHRA approval for sotatercept, marketed as Winrevair, to treat PAH in the adult population.

KOLs interviewed by GlobalData stressed the lack of biologic therapies specifically targeting T2-low asthma.

HUTCHMED (China) has entered into agreements to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals (SHPL) ...

Effective management of atopic dermatitis (AD) has been one of the top priorities for physicians over the years, as quality of life in these patients is compromised due to the disruptive symptoms that ...

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

Innovent and Roche have entered a partnership and exclusive licence agreement to accelerate the development of IBI3009.

Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m.

Coronavirus Disease 2019 (COVID-19) vaccine 2 is under clinical development by Sinopharm Group and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Rifaximin is under clinical development by Nexpharm Korea and currently in Phase I for Irritable Bowel Syndrome.